Osteonectin overexpression in the case of prostate cancer with intraluminal inclusions by Піддубний, Артем Михайлович et al.
OFP-13-011
Multi-stage pathological and immunohistochemical characterisation
of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced murine bladder
cancer
J. Fontugne*, J. Wong, N. Karboul, R. Leclerc, A. Nicolas, D. Meseure,
Y. Allory, I. Bernard-Pierrot, F. Radvanyi, M. Sibony
*Institut Curie, UMR 144 Molecular Oncology, Paris, France
Background & Objective: N-butyl-N-(4-hydroxybutyl)-nitrosamine
(BBN)-induced bladder tumours in mice represent an attractive
model of muscle-invasive bladder cancer (MIBC), which mimicks
the basal-like transcriptomic subgroup. Lineage tracing studies in
mice suggested that MIBC, including basal tumours, arise from
carcinoma in situ (CIS) lesions. However, in routine pathology prac-
tice, the majority of human CIS express a luminal immunohisto-
chemical (IHC) phenotype CK20+. In this context, we sought to
characterize early stage lesions occurring in BBN-exposed mice,
using IHC markers of basal and luminal subtypes
Method: To study multiple stages of tumour progression, 35 mice blad-
ders were obtained at different time points following oral BBN exposure
of a maximum of 14 weeks. Morphological and IHC analysis of basal
(CK5, CK6, CK14), luminal (CK20, GATA3, FOXA1) and proliferation
(Ki67) markers were performed.
Results: Morphological analysis identified a spectrum of lesions during
BBN exposure, including isolated early lesions -hyperplasia (n=1), dysplasia
(n=3) or CIS (n=4)- pTa (n=13), pT1 tumours (n=10) and MIBCs (pT2 and
pT3, n= 6). Squamous differentiation was observed in 79% of pTa-pT3
tumours. A basal IHC pattern was identified in 2 of 3 dysplasia lesions and
in all CIS lesions, whichwere associatedwith high proliferation (Ki67≥20%).
pTa to pT3 cases displayed a basal-like phenotype in 86% of cases.
Conclusion:Our study shows that BBN-induced bladder tumours at both
CIS and invasive stages are of basal-like IHC phenotype, suggesting that
BBN-treated mice may represent a model of basal CIS. Further genomic
and transcriptomic analyses of stage-specific lesions following laser-
capture microdissection are ongoing.
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Osteonectin overexpression in the case of prostate cancer with
intraluminal inclusions
A. Piddubnyi*, R. Moskalenko, I.-M. Radomychelski, M. Lyndin, V.
Sikora, A. Romaniuk
*Sumy State University, Pathology Dept., Ukraine
Background&Objective:Osteonectin (OSN) is secreted by osteoblasts
during bone formation, initiating mineralization and promoting mineral
crystal formation at sites of ectopic calcification. Also OSN was found in
many types of human malignant tumours. The aim is to study the OSN
expression in patients with prostate cancer (PC) and the presence of
intraluminal inclusions (prostatolithes and amyloid cells).
Method:OSNexpressionwas investigated in tumours and in the adjacent
prostatic tissue of 30 PCswith intraluminal inclusions and 30 PCswithout
them by immunohistochemistry. In each group 15 samples refer to mod-
erately differentiated G2 and low-differentiated G3 tumours. Samples
were fixed, embedded in paraffin, and analized for OSN accumulation
using the anti-OSN antibody, followed by DAB detection substrate and
counterstained with Mayer’s haematoxylin.
Results: OSN expression was increased in PC tissues with pathological
inclusions in comparison to those without them (p<0.001, Student test).
Osteonectin was mostly localized in tumour cells cytoplasm, its expres-
sion was not observed in tumour microangiourea cells and in stroma. It
was found that the OSN expression by tumour cells reduced during re-
duction of themalignant tumour differentiation (comparison of subgroups
G2 and G3) (p<0.001 and p<0.01 respectively for groups I and II).
Conclusion:OSN overexpression in tumours and in the adjacent prostat-
ic tissue of PCs with intraluminal inclusions may be regarded as a
prospective role for the osteosteogenic phenotype development of tumour
cells and for the bone metastasis promotion.
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Differentiated thyroid carcinoma of the paediatric age: genetic and
clinical scenario
F. Galuppini*, P. Facchin, S. Barollo, S. Watutantrige-Fernando, F.
Vianello, A. Fassina, M. Rugge, C. Mian, G. Pennelli
*Università Studi di Padova, DIMED, Italy
Background & Objective: Follicular-derived differentiated thyroid car-
cinoma is the most common endocrine malignancy in children. The dif-
ferent clinical and pathological features between paediatric and adult
thyroid carcinomas could be related to a different genetic profile.
However, few studies are currently available and most of them involved
a limited number of patients and mostly focused on radiation-exposed
population. A greater knowledge of the genetics might improve the diag-
nostic frame and lead to an individualized therapy.
Method: We studied 57 paediatric patients who underwent surgery for
diagnosis of differentiated thyroid carcinoma between 2000 and 2017.
The presence of mutations in BRAF, NRAS, PTEN, PIK3CA genes,
and in TERT promoter, were analyzed through sequencing. RET/PTC
rearrangement has been investigated with Fluorescent in situ hybridiza-
tion. Clinical-molecular features of paediatric patients were compared
with those of 165 adult patients.
Results: In paediatric age, male gender and subjects < 15 years have a
more extensive disease and more frequent lymph nodes and distant me-
tastasis. Compared to adults, in paediatric patients there is a more fre-
quency of lymph nodes and distant metastasis (p=0,01); moreover, pae-
diatric patients are more prone to have a second treatment (p<0,01). The
frequency of BRAFV600E mutation is lower in paediatric DTCs
(p<0,01). NRASQ61R, NRASQ61K and TERTC250T are rare in chil-
dren and adolescents; no mutations were found in PTEN and in PIK3CA.
Conclusion: Paediatric differentiated-thyroid cancer has a greater aggres-
siveness at diagnosis and a greater risk of recurrence than adult’s one.
Differently from adult, point mutations have not a genetic key role.
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Specific molecular mechanisms of tumour progression from well dif-
ferentiated to poorly differentiated thyroid carcinomas identified by
next generation sequencing analysis
M. Volante*, S. Vatrano, S. Carollo, J. Giorcelli, A. Votta, L. Daniele, G.
De Rosa, M. Papotti
*University of Turin, Dept. of Oncology, Orbassano, Turin, Italy
Background & Objective: The molecular background of thyroid cancer
histotypes, including poorly differentiated carcinoma, has been investi-
gated in recent years using high throughput technologies. However, mo-
lecular studies specifically designed to explore the mechanism of tumour
progression from well-to-poorly differentiated forms are still missing
Method: Fifteen cases of poorly differentiated carcinomas with associat-
ed well-differentiated papillary or follicular components have been
micro-dissected to isolate and characterize at the molecular level the
two tumour populations using the Oncomine Focus Assay (IonTorrent
platform, ThermoFisher Scientific) covering somatic CNA and fusions in
52 cancer relevant genes
Results: Eleven cases yielded adequate DNA and RNA for next genera-
tion sequencing analysis. A high prevalence of alterations in the RAS (5/
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